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Résumé en
anglais
AIM: This study was designed to estimate the percentage of growth hormone (GH)-
treated children born small for gestational age (SGA), with serum IGF-1 >2 SDS
before and after GH dose adaptation. METHODS: SGA boys aged 4-9 and girls aged
4-7 with a height <-2 SDS and an annual growth rate below the mean received a
subcutaneous GH dose of 57 mug/kg/day for 2 years. The GH dose was to be
decreased by 30% in children with serum IGF-1 >2 SDS at 12 months and on the
previous sample. The GH dose could be reduced a second time to 35 mug/kg.day.
IGF-1 and IGFBP-3 dosages were centralized. RESULTS: Among the 49 (21 boys)
children included in the study, 8 (16.3%) had an IGF-1 >2 SDS consecutively at 9
and 12 months (95% CI 7.3, 29.7). The GH dose was decreased in 6/8 children.
However, IGF-1 levels were elevated at several nonconsecutive determinations in
45% (95% CI 28.4, 56.6) of the patients. CONCLUSION: A high IGF-1 level is
observed in 45% of the GH SGA-treated children with a relatively high dose of GH. A
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